A robustness-based approach to systems-oriented drug design
The DOI matches its Crossref record; 104 of the 105 references it cites were found in a registry or an index.
Abstract
Many potential drugs that specifically target a particular protein considered to underlie a given disease have been found to be less effective than hoped, or to cause significant side effects. The intrinsic robustness of living systems against various perturbations is a key factor that prevents such compounds from being successful. By studying complex network systems and reformulating control and communication theories that are well established in engineering, a theoretical foundation for a systems-oriented approach to more effectively control the robustness of living systems, particularly at the cellular level, could be developed. Here, I use examples that are based on existing drugs to illustrate the concept of robustness, and then discuss how a greater consideration of the importance of robustness could influence the design of new drugs that will be intended to control complex systems.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“it is commonly the case in complex biochemical networks that while changes in individual parameters have little effect on the behaviour of biochemical pathways—indeed evolution is thought to have selected for robustness to individual parameter changes”
Citations
Cites
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
The Byzantine generals problem
Lamport, L., Shostak, R., & Pease, M. (1982) · ACM Transactions on Programming Languages and Systems · doi:10.1145/357172.357176 · Cited by 6,023 · cited 1×
“Fail-on failure (also known as Byzantine failure) has been a major problem for communication networks, and is considered to be a crucial problem in complex network systems in genera”
BackgroundDruker, B. J., Talpaz, M., Resta, D. J., Peng, B., Buchdunger, E., Ford, J. M., Lydon, N. B., Kantarjian, H., Capdeville, R., Ohno-Jones, S., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441401 · Cited by 5,243 · cited 1×
“A further illustrative case is that of imatinib (Gleevec; Novartis), which is considered as a successful example of a drug that targets the protein product of a disease-causative gen”
BackgroundROWLEY, J. D. (1973) · Nature · doi:10.1038/243290a0 · Cited by 4,291
EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044238 · Cited by 3,964
Cobleigh, M. A., Vogel, C. L., Tripathy, D., Robert, N. J., Scholl, S., Fehrenbacher, L., Wolter, J. M., Paton, V., Shak, S., Lieberman, G., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.9.2639 · Cited by 2,765
Epidermal growth factor-related peptides and their receptors in human malignancies
Salomon, D. S., Brandt, R., Ciardiello, F., & Normanno, N. (1995) · Critical Reviews in Oncology/Hematology · doi:10.1016/1040-8428(94)00144-i · Cited by 2,690
Khan, J., Wei, J. S., Ringnér, M., Saal, L. H., Ladanyi, M., Westermann, F., Berthold, F., Schwab, M., Antonescu, C. R., Peterson, C., et al. (2001) · Nature Medicine · doi:10.1038/89044 · Cited by 2,644
Cited by
Items 401–500 of 535
AI-driven Automated Discovery Tools Reveal Diverse Behavioral Competencies of Biological NetworksPreprint
Etcheverry, M., Moulin-Frier, C., Oudeyer, P., & Levin, M. G. (2024) · eLife · doi:10.7554/elife.92683.3 · Cited by 3
Reprogrammation comportementale : modèles, algorithmes et application aux maladies complexes
Biane, C. (2018) · theses.fr (ABES) · doi:10.70675/2c367370z3ea6z46cez997czc25478fd2287 · Cited by 3
Targeted Protein Upregulation of STING for Boosting the Efficacy of Immunotherapy
Cho, W., Won, S., Choi, Y., Yi, S., Park, J. B., Park, J., Kim, C. E., Narayana, C., Kim, J. H., Yim, J., et al. (2023) · Angewandte Chemie · doi:10.1002/ange.202300978 · Cited by 2
Introduction to Pathway Analysis
Yuryev, A. (2008) · Wiley eBooks · doi:10.1002/9780470399279.ch1 · Cited by 2
“Once formed, the disease network should be resilient to drugs precisely because of the robustness that has enabled its existence in the fi rst place [30] .”
BackgroundSoftware Platform for Systems Biology
Asai, Y., Abé, T., Matsuoka, Y., Ghosh, S., & Kitano, H. (2014) · Drug Delivery System · doi:10.2745/dds.29.386 · Cited by 2
Self-citationThe Theory of Biological Robustness and its Implication to Cancer
Kitano, H. (2009) · Wiley eBooks · doi:10.1002/9780470437988.ch16 · Cited by 2
Self-citationComplexities in Quantitative Systems Analysis of Signaling Networks
Kiel, C., & Serrano, L. G. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-405926-9.00005-8 · Cited by 2
Reichle, A., Gerner, C., & Haegeman, G. (2013) · Springer eBooks · doi:10.1007/978-94-007-6866-6_11 · Cited by 2
Current and Future Strategies for Improving Drug Discovery Efficiency
Njogu, P., & Chibale, K. (2015) · Wiley eBooks · doi:10.1002/9781118819586.ch11 · Cited by 2
Oncogenic Signalling Networks and Polypharmacology as Paradigms to Cope with Cancer Heterogeneity
Moya‐García, A. A., Morilla, I., & Ranea, J. A. G. (2014) · Current Proteomics · doi:10.2174/157016461103140922164228 · Cited by 2
Chemoinformatic Approaches to Target Identification
Gregori‐Puigjané, E., & Keiser, M. J. (2012) · Royal Society of Chemistry eBooks · doi:10.1039/9781849734912-00050 · Cited by 2
Plant Pharmacogenomics: From Drug Discovery to Personalized Ethnomedicine
Babar, M. M., Zaidi, N. U. S. S., & Gul, A. (2015) · Springer eBooks · doi:10.1007/978-81-322-2172-2_25 · Cited by 2
Matera, R. (2009) · AMS Dottorato Institutional Doctoral Theses Repository (University of Bologna) · doi:10.6092/unibo/amsdottorato/1711 · Cited by 2
Is it Time to Revisit the Current R&D Model?
O’Connell, D. P., Hopkins, A. L., & Roblin, D. (2007) · International Journal of Pharmaceutical Medicine · doi:10.2165/00124363-200721050-00004 · Cited by 2
Rule-based whole body modeling for analyzing multi-compound effects
Hwang, W., Hwang, Y., Lee, S., & Lee, D. (2012) · Data and Text Mining in Bioinformatics · doi:10.1145/2390068.2390083 · Cited by 2
“When drug-induced inhibition of proteins is happened, a disease network mostly has complementary signaling pathways for bypassing the inhibition of proteins [5].”
BackgroundGravid Uterus as a Soft Biological Shell
Miftahof, R. N., & Nam, H. G. (2011) · Springer eBooks · doi:10.1007/978-3-642-21473-8_9 · Cited by 2
Language and Hardware Acceleration Backend for Graph Processing
Mokhov, A., de Gennaro, A., Tarawneh, G., Wray, J., Lukyanov, G., Mileiko, S., Scott, J., Yakovlev, A., & Brown, A. D. (2018) · Lecture notes in electrical engineering · doi:10.1007/978-3-030-02215-0_4 · Cited by 2
Bizzarri, M., Minini, M., & Monti, N. (2020) · Human perspectives in health sciences and technology · doi:10.1007/978-3-030-32857-3_1 · Cited by 2
Zhou, S., Duan, Y., Deng, Y. L., Wang, M., Huang, C., Liu, Z., Xu, X., & Lv, W. (2021) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2021/6693472 · Cited by 2
“+e traditional theory of “single compound”-“single target” cannot satisfy the research of “multicompound”-“multitarget”-“multipathway” interaction of TCM [24].”
Houriet, J., Wolfender, J., & Graz, B. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-90999-0.00003-3 · Cited by 2
Molecular Dynamics Simulations
Schlick, T. (2015) · Springer eBooks · doi:10.1007/978-3-540-70529-1_88 · Cited by 2
Fragile robustness: principles and practice
Quinton-Tulloch, M. J. (2012) · Research Explorer (The University of Manchester) · Cited by 2
Genetic Influencers in Gene Regulatory Networks
Makse, H. A., & Zava, M. (2024) · Understanding complex systems · doi:10.1007/978-3-031-78058-5_5 · Cited by 1
Ejeta, B. M., & Das, M. K. (2026) · Journal of Pharmaceutical Innovation · doi:10.1007/s12247-026-10664-1 · Cited by 1
Network Pharmacology: A New Paradigm in Drug Discovery & Development
Sandeep, M., & Babu*, P. V. (2023) · International Journal of Pharmaceutical and Biological Science Archive · Cited by 1
Systems Biology for the Study of Multiple Sclerosis
Villoslada, P., & Steinman, L. (2013) · Springer eBooks · doi:10.1007/978-1-4614-7953-6_12 · Cited by 1
Human MicroRNA Targetome Indicates a Specialized Role of MicroRNAs in Regulation of Oncogenesis
Satoh, J. (2012) · Springer eBooks · doi:10.1007/978-94-007-4819-4_10 · Cited by 1
Integrative Systems Biology I—Biochemistry: Phase I Lead Discovery and Molecular Interactions
Prokop, A., & Michelson, S. (2012) · SpringerBriefs in pharmaceutical science & drug development · doi:10.1007/978-94-007-2849-3_3 · Cited by 1
Les nouvelles cibles thérapeutiques dans le cancer du rein
Méric, J., Billemont, B., & Rixe, O. (2010) · Bulletin du Cancer · doi:10.1684/bdc.2010.1070 · Cited by 1
Kitano, H. (2012) · Elsevier eBooks · doi:10.1016/b978-0-12-385944-0.00024-1 · Cited by 1
Self-citationApplications of genome-scale metabolic network models in the biopharmaceutical industry
Kim, H. U., & Lee, S. Y. (2013) · Pharmaceutical Bioprocessing · doi:10.4155/pbp.13.37 · Cited by 1
Epistructure-Based Design of Drugs with Controlled Promiscuity
Fernández, A. (2016) · Soft and biological matter · doi:10.1007/978-3-319-30852-4_13 · Cited by 1
Strategies for Expanding Access and Improving the Quality of Pharmaceutical Services
Dias-Souza, M. V. (2017) · IGI Global eBooks · doi:10.4018/978-1-5225-2237-9.ch003 · Cited by 1
Huang, X., Wen, Y., Xie, Q., Lou, S., Guo, B., Liang, C., Chen, Y., & Lu, Z. (2018) · Dissolution Technologies · doi:10.14227/dt250218p26 · Cited by 1
Metabolomics in Medicinal Plant Research
Kandan, A., & Yang, N. (2012) · Springer eBooks · doi:10.1007/978-3-642-29974-2_12 · Cited by 1
Software Platform for Metabolic Network Reconstruction of Mycobacterium tuberculosis
Ghosh, S., Matsuoka, Y., Asai, Y., Kitano, H., Bhardwaj, A., Scaria, V., Vashisht, R., Shah, A. D., Mondal, A. K., Vishnoi, P., et al. (2012) · Springer eBooks · doi:10.1007/978-1-4614-4966-9_2 · Cited by 1
Self-citationDrug Discovery: Small Molecule Drugs
Ng, R. (2008) · Drugs · doi:10.1002/9780470403587.ch3 · Cited by 1
Casagrande, A., & Piazza, C. (2015) · Theoretical Computer Science · doi:10.1016/j.tcs.2015.02.045 · Cited by 1
“The “unwanted interactions” mentioned by Kitano [18] are the interference e ff ects we intend to measure with low level observational equivalences.”
BackgroundInfluentialBioinformatics for Diseases Management: A Personalized Therapeutics Prospective
Kanhaiya, K. (2017) · Springer eBooks · doi:10.1007/978-3-319-63633-7_11 · Cited by 1
Characterization of Drug–Protein Interactions by Chemoproteomics
Schirle, M., Bantscheff, M., & Küster, B. (2019) · Wiley eBooks · doi:10.1002/9781119081661.ch10 · Cited by 1
DNA complexes as an efficient gene anticancer drug delivery therapy
Madkour, L. H. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-819777-6.00020-2 · Cited by 1
Singh, P. C., & Omer, A. (2020) · Pharmacognosy Magazine · doi:10.4103/0973-1296.301874 · Cited by 1
秦, 齐. (2022) · Traditional Chinese Medicine · doi:10.12677/tcm.2022.112043 · Cited by 1
Pálfy, M., Földvári-Nagy, L., Módos, D., Lenti, K., & Korcsmáros, T. (2013) · Springer eBooks · doi:10.1007/978-94-007-6803-1_16 · Cited by 1
“, increasing robustness in healthy cells and decreasing robustness in cancerous cells during chemotherapy [43, 44].”
Longevity genes across species: Conservation versus evolvability
Salvioli, S., Tieri, P., Castellani, G., Capri, M., Barbi, C., Santoro, A., Altilia, S., Invidia, L., Pierini, M., Bellavista, E., et al. (2007) · Invertebrate survival journal · Cited by 1
Systems biology of cellular signaling : quantitative experimentation and systems genetics approaches
Taylor, R. J. (2009) · cIRcle (University of British Columbia) · doi:10.14288/1.0067122 · Cited by 1
Integrated approach to study Ras-dependent cancer metabolic rewiring in mouse fibroblasts
Sanctis, G. D. (2017) · BOA (University of Milano-Bicocca) · Cited by 1
Omollo, C. (2017) · Open University of Cape Town (University of Cape Town) · Cited by 1
Avaliação do efeito antiproliferativo da apocinina e diapocinina em células de osteossarcoma humano
Matos, A. A. (2018) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.25.2018.tde-24052018-175418 · Cited by 1
Bow-tie motifs enable protein multifunctionality by connecting cellular processes in the interactomePreprint
Niss, K., Hu, J. X., Gómez‐Casado, C., Joeris, T., Agace, W. W., Belling, K., & Brunak, S. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/495895 · Cited by 1
Robustness and entropy for dynamics on networks
Schwarze, A. C. (2019) · Oxford University Research Archive (ORA) (University of Oxford) · doi:10.5287/ora-qyaobdpeo · Cited by 1
Topics in Nucleic Acids Structure: DNA Interactions and Folding
Schlick, T. (2010) · Interdisciplinary applied mathematics · doi:10.1007/978-1-4419-6351-2_6 · Cited by 1
AI-driven Automated Discovery Tools Reveal Diverse Behavioral Competencies of Biological NetworksPreprint
Etcheverry, M., Moulin-Frier, C., Oudeyer, P., & Levin, M. G. (2024) · eLife · doi:10.7554/elife.92683.1 · Cited by 1
Valencia, P. M. (2013) · DSpace@MIT (Massachusetts Institute of Technology) · Cited by 1
From Cancer Drivers to Cancer Keepers: Paradigm Shift and Clinical ImplicationsPreprint
Zhang, X., & Zhang, W. (2025) · arXiv (Cornell University) · doi:10.48550/arxiv.2508.16128 · Cited by 1
Integrating cell-level kinetic modeling into the optimization of cancer therapeutics
Krippendorff, B. (2010) · Maynooth University ePrints and eTheses Archive (Maynooth University)
Data Integration with Biological PathwaysPreprint
van Iersel, M. (2022) · Thesis Commons (OSF Preprints) · doi:10.31237/osf.io/d6g3a
A new Ligand-Based approach to virtual screening, and prolifing or large chemical libraries
Gregori‐Puigjané, E. (2008) · Repositori digital de la UPF (Universitat Pompeu Fabra)
Introduction to Assay Development
Wu, G. (2010) · Wiley eBooks · doi:10.1002/9780470583128.ch1
Systemic similarity analysis of compatibility drug-induced multiple pathway patterns in vivoPreprint
Wang, Z., Zhang, Z., Wáng, Y., Cheng, Y., Tong, W., & Wang, Y. (2008) · Nature Precedings · doi:10.1038/npre.2008.1688.1
Sun, J., Hart, P., & Zhao, Z. (2011) · IEEE International Conference on Bioinformatics and Biomedicine Workshops (BIBMW) · doi:10.1109/bibmw.2011.6112387
“Limitations of drug efficacy can be caused by the intrinsic robustness of biological networks, of which the targets are only a part, whereas adverse side effect of a drug may be caused by unwanted cross-reactivity with other biologically relevant targets [3, 4].”
BackgroundRobustness Analysis of Cellular Systems for In Silico Drug Discovery
Perumal, T. M., Wu, Y. L., & Gunawan, R. (2008) · IFAC Proceedings Volumes · doi:10.3182/20080706-5-kr-1001.02133
“Thus, the understanding of robustness and its tradeoffs in cellular systems can greatly benefit the drug discovery efforts for human diseases (Kitano, 2007).”
BackgroundRobustness perspective on network-based prediction of gene essentiality
Liu, W., Ding, D., & Li, N. (2009) · Chinese Control and Decision Conference (CCDC) · doi:10.1109/ccdc.2009.5191705
“I.e., robustness allows changes in the structure and components, but specific functions must be maintained [ 16 ].”
BackgroundDevelopment of a multi-component drug from turmeric using central composite design
Zhang, X., Han, S., Li, Y., & Jiang, J. (2014) · Frontiers of Chemical Science and Engineering · doi:10.1007/s11705-014-1439-5
“Meanwhile, single agent therapy has sometimes proven to be ineffective to treat complex diseases because the diversities of cellular functions and interactions among various pathways can limit the performance of singletarget drugs [3].”
BackgroundDrug Discovery in the Post-Genomic Era: Systems-Based Drug Discovery
Hu, Z. (2007) · International Conference on Bioinformatics and Biomedical Engineering · doi:10.1109/icbbe.2007.107
“Even diseases viewed as relatively simple which may be caused by a single gene defect; there are many systems properties that confound it [11].”
BackgroundPark, H. (2015) · Scholarworks@UNIST (Ulsan National Institute of Science and Technology)
LA BIOLOGIA DE SISTEMES: LA BIOLOGIA DEL SEGLE XXI?
Nájera, E. Y. I., Lluch‐Senar, M., & Serrano, L. G. (2012) · Treballs de la Societat Catalana de Biologia · doi:10.2436/tscb.vi.60965
Multitarget Control of Drug Impact: A Therapeutic Imperative in Cancer Systems Biology
Fernández, A. (2015) · Springer eBooks · doi:10.1007/978-3-319-16850-0_13
Comparative Analysis of Motifs in Giant Strong Component of Metabolic Networks
Liu, W., & Ding, D. (2009) · International Conference on Computational Intelligence and Natural Computing (CINC) · doi:10.1109/cinc.2009.231
“Since Ma and Zeng proposed the “bow tie” structure of metabolic networks [11], it is increasingly recognized as being a conserved property of complex biological networks, as highlighted by recent studies [13-16], and the results suggest that this structure property is functional meaningful for metabolism, disease and…”
BackgroundChagnon, F. (2014) · Knowledge UdeS (Institutional Deposit of the University of Sherbrooke)
Gene Expression Profiling and Pathway Analysis for Identification of Molecular Targets in MS
Satoh, J. (2013) · Springer eBooks · doi:10.1007/978-1-4614-7953-6_11
Spectral Theory for the Robustness and Dynamical Properties of Complex Networks
Taylor, D. (2013) · CU Scholar (University of Colorado Boulder)
Interaction patterns in diabetes mellitus II network: An RMT relationPreprint
Jalan, S., Rai, A., & Pawar, A. K. (2014) · arXiv (Cornell University) · doi:10.48550/arxiv.1410.2071
Reichle, A., & Hildebrandt, G. C. (2013) · Springer eBooks · doi:10.1007/978-94-007-6866-6_20
Botvinnik, A. (2009) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-3281
Rosado, J. O., Bonatto, D., & Henriques, J. A. P. (2010) · Americanae (AECID Library) · doi:10.13140/rg.2.2.23777.12647
Establishment of a novel technique to study G protein-coupled receptor activation
Djannatian, M. (2011) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-1060
Gene and protein networks in understanding cellular function
Lehtinen, S. (2015) · UCL Discovery (University College London)
Fernández, A. (2016) · Soft and biological matter · doi:10.1007/978-3-319-30852-4_12
Satoh, J. (2012) · Advances in bioinformatics and biomedical engineering book series · doi:10.4018/978-1-4666-2196-1.ch032
Predictive Optimization of Pharmaceutical Efficacy
Wang, H. (2014) · eScholarship (California Digital Library)
APPLICATION OF GRAPH MODELS IN BIOINFORMATICS
Ligeti, B. (2016) · REAL-PhD (Hungarian Academy of Sciences)
Network analysis to model diseases and cellular reprogramming for therapeutic intervention
Crespo, I. (2013) · Open Repository and Bibliography (University of Luxembourg)
α2B-ADRENOCEPTORS IN THE REGULATION OF VASCULAR SMOOTH MUSCLE CELL CONTRACTION AND PROLIFERATION
Huhtinen, A. (2017) · UTUPub (University of Turku)
Blending biology and chemistry to enable systems pharmacology
Duran‐Frigola, M. (2016) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
Medicine in New Era with Artificial Intelligence and Systems Biology
Asai, Y., Abé, T., & Hayano, T. (2018) · Japanese Journal of Radiological Technology · doi:10.6009/jjrt.2018_jsrt_74.11.1343
Computational Models of Cell Cycle Transitions
Hernansaiz-Ballesteros, R. D., Jenkins, K., & Csikász‐Nagy, A. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-8618-7_14
Cokkinos, D. V. (2019) · Springer eBooks · doi:10.1007/978-3-319-98186-4_4
Statistical Characterization of Biochemical Network Models
Biddle-Snead, C. (2013) · eScholarship (California Digital Library)
Towards systems pharmacology models of druggable targets and disease mechanisms
Knight-Schrijver, V. R. (2018) · Apollo (University of Cambridge) · doi:10.17863/cam.36977
Combinational delivery therapies of nucleic acids for cancer treatment
Madkour, L. H. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-819777-6.00015-9
Modelling for regenerative medicine: systems biology meets systems chemistry
Winkler, D. A., Halley, J. D., & Burden, F. R. (2009)
Investigating mechanisms of acquired resistance to AT13148, an AGC kinase inhibitor
Breeds, N. (2020) · Kent Academic Repository (University of Kent)
Modeling regulatory processes with qualitative networks
Schwab, J. D. (2020) · OPen Access Repositorium der Universität Ulm (OPARU) (Ulm University) · doi:10.18725/oparu-32473
Mayer, P. (2020) · PLoS ONE · doi:10.1371/journal.pone.0239841
“Differential complexity translates into differential robustness, and it appears in this model as a 543 novel class of therapeutic target [29].”
Anvar, S. A. A. (2012) · Leiden Repository (Leiden University)
Rahman, K. M. T., Islam, M. F., Saha, S., & Billah, M. M. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.03.21.436331
“In the recent two 80 decades, the genomic and proteomic research-driven that a single disease-causing element 81 can act as a panacea for cancer, diabetes, and other complex diseases which are known as a 82 magic bullet but some of them showed positive effects [18].”
BackgroundMATHEMATICAL MODELING AND INFERENCE OF CANCER NETWORKS
Vundavilli, V. S. (2021) · OakTrust (Texas A&M University Libraries)
Fulfilling a Therapeutic Imperative in Cancer Treatment: Control of Multi-target Drug Impact
Fernández, A. (2010) · Springer eBooks · doi:10.1007/978-3-642-11792-3_10
Metadata
- Authors
- Kitano, H.
- Affiliations
- Sony Computer Science Laboratories (JP)
- Corresponding author
- Kitano, Hiroaki
- ORCID
- Kitano, Hiroaki
- Venue
- Nature Reviews Drug Discovery
- Published
- 2007-02-23
- Volume
- 6
- Issue
- 3
- Pages
- 202-210
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W1504533062
- Cited by
- 488
- References
- 105
- Citations by year
- 2026: 5 · 2025: 4 · 2024: 9 · 2023: 6 · 2022: 15 · 2021: 8 · 2020: 18 · 2019: 20 · 2018: 16 · 2017: 25 · 2016: 29 · 2015: 37 · 2014: 30 · 2013: 32 · 2012: 47
- FWCI
- 3.59
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gene Regulatory Network Analysis
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bioinformatics and Genomic Networks
- Keywords
- robustness, biological robustness, complex networks, control theory, communication theory, cellular systems, drug efficacy, adverse drug reactions, systems biology
- MeSH terms
- Animals, Communicable Diseases, Pharmaceutical Preparations, Humans, Models, Theoretical, Neoplasms, Technology, Pharmaceutical, Drug Design, Signal Transduction, Cell Proliferation, Drug-Related Side Effects and Adverse Reactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.